The compounds that dominate weight-loss research - retatrutide (triple agonist), tirzepatide, semaglutide and cagrilintide, plus the GH-axis veteran tesamorelin and the HGH fragment AOD-9604. Ranked by mechanism and reported trial data, honest about what is approved versus investigational and where AOD-9604 fell short. Research use only.

Trump, Retatrutide and the Obesity-Drug Demand Story

The White House denies that Donald Trump got early compassionate-use access to retatrutide, an experimental obesity drug still in Eli Lilly trials. What the story says, what compassionate use is, why retatrutide is not approved before 2027, and why research use only is a separate category from human use.

The Half-Life Arms Race: Why Peptides Are Engineered to Last

Nearly every modern peptide program is, underneath, a half-life-engineering project - acylation, PEGylation, Fc fusion, once-weekly to once-monthly. A field map of that arms race, and the near-empty frontier it leaves behind: designing for rhythm, not duration. Research use only.

Beyond GLP-1: Amylin, Glucagon, GIP and the Next Obesity Research Wave

Obesity research has moved past GLP-1 alone. This hub maps the next-generation mechanisms - GIP agonism and antagonism, glucagon, and amylin - and the candidate landscape from tirzepatide and retatrutide to MariTide, CagriSema, survodutide, amycretin and petrelintide. Research use only.

Orforglipron: a research guide to the first oral non-peptide GLP-1

Eli Lilly's once-daily oral small-molecule GLP-1 receptor agonist - not a peptide. Mechanism, the ATTAIN Phase 3 data (~12.4% at 72 weeks), why a pill changes access, and how it differs from the research peptides. Research use only.

MariTide (Maridebart Cafraglutide): The Once-Monthly GLP-1/GIP Research Profile

Amgen's once-monthly peptide-antibody conjugate pairs GLP-1 agonism with GIP antagonism - the unusual mechanism, the Phase 2 data (up to ~20%), and where it sits in the obesity pipeline. Research use only.

CagriSema & Cagrilintide: The Amylin + GLP-1 Combo Explained

Novo Nordisk's combination of cagrilintide (an amylin analogue) and semaglutide (a GLP-1 agonist) - the mechanism, the REDEFINE Phase 3 data (~20-23%), and why amylin is the next obesity-research mechanism. Research use only.

Amycretin: Novo Nordisk's GLP-1 and Amylin Candidate Explained

Novo Nordisk's investigational single-molecule GLP-1 and amylin receptor agonist in oral and injectable development - the science, the early data (~22% injectable at 36 weeks), and how it compares to CagriSema. Research use only.

Survodutide: GLP-1, Glucagon and the MASH Opportunity

Boehringer Ingelheim's investigational GLP-1 / glucagon dual agonist studied for obesity and MASH - the mechanism, the SYNCHRONIZE program, the ~16.6% Phase 3 weight loss, and the distinctive liver-fat angle. Research use only.

Petrelintide: Zealand and Roche's Amylin Analogue Explained

Zealand Pharma and Roche's investigational long-acting amylin analogue - the amylin-first obesity strategy, the Phase 2 data (~10.7% at week 42), and why an amylin-only approach matters. Research use only.

Research use only. These articles summarise public literature and catalogue facts. They do not diagnose, treat, or prevent any disease, and are not medical advice.

Browse the full catalogue

PRECISION. PURITY. PERFORMANCE.

Research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical & Freedom Diagnostics, with Certificates of Analysis published per released batch. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research

Support

Ways to Pay

Shop by goal

Muscle & IGF Research

Tissue and Cellular Models

Regenerative Research

Cellular Senescence Research

Cognitive Research

Multi-Compound Blends

Shop by compound

CJC-1295 (without DAC)

Shop by region

Research use only (RUO). All products are sold strictly for laboratory and research purposes — not for human or veterinary consumption. Purchasers must be 21 or older.

Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.

Research use only — not for human consumption. All products are supplied strictly for laboratory research purposes.